4.945

1.88% -0.115

Myriad Genetics Inc (MYGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MYGN? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$5.06

Offen:

$4.91

24-Stunden-Volumen:

1.01M

Relative Volume:

0.84

Marktkapitalisierung:

$463.80M

Einnahmen:

$824.50M

Nettoeinkommen (Verlust:

$-365.90M

KGV:

-1.2509

EPS:

-3.9531

Netto-Cashflow:

$-25.60M

1W Leistung:

-3.22%

1M Leistung:

+9.60%

6M Leistung:

-31.42%

1J Leistung:

-52.31%

1-Tages-Spanne:

$4.75

$5.105

1-Wochen-Bereich:

$4.75

$5.47

52-Wochen-Spanne:

$3.76

$10.47

Myriad Genetics Inc Stock (MYGN) Company Profile

Firmenname

Myriad Genetics Inc

Sektor

Healthcare (1115)

Branche

Diagnostics & Research (53)

Telefon

801-584-3600

Adresse

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Mitarbeiter

2,700

Twitter

@myriadgenetics

Nächster Verdiensttermin

2025-02-24

Neueste SEC-Einreichungen

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, A, WAT

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MYGN Myriad Genetics Inc	4.96	473.15M	824.50M	-365.90M	-25.60M	-3.9531
TMO Thermo Fisher Scientific Inc	476.77	184.15B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	188.30	137.93B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	578.50	47.82B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	111.79	32.62B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	287.74	29.19B	3.17B	642.63M	516.49M	10.77

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-21	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2025-05-08	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-05-07	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-04-09	Herabstufung	Guggenheim	Buy → Neutral
2025-03-12	Hochstufung	Piper Sandler	Neutral → Overweight
2025-02-12	Eingeleitet	Craig Hallum	Buy
2024-12-10	Eingeleitet	UBS	Neutral
2024-12-09	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-19	Eingeleitet	Morgan Stanley	Equal-Weight
2024-08-28	Eingeleitet	Wells Fargo	Overweight
2024-06-27	Eingeleitet	Scotiabank	Sector Outperform
2024-06-03	Fortgesetzt	Jefferies	Underperform
2024-05-08	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-12-21	Fortgesetzt	Piper Sandler	Neutral
2023-12-19	Eingeleitet	Wells Fargo	Equal Weight
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-07-05	Fortgesetzt	JP Morgan	Underweight
2023-05-23	Hochstufung	Goldman	Sell → Buy
2023-01-18	Hochstufung	Raymond James	Mkt Perform → Outperform
2022-10-06	Eingeleitet	Stephens	Equal-Weight
2021-10-15	Fortgesetzt	Cowen	Market Perform
2021-06-15	Eingeleitet	Raymond James	Mkt Perform
2021-06-03	Eingeleitet	Goldman	Sell
2019-09-26	Herabstufung	BofA/Merrill	Neutral → Underperform
2019-08-14	Herabstufung	Piper Jaffray	Overweight → Neutral
2019-08-02	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-08-01	Hochstufung	Barclays	Underweight → Equal Weight
2019-07-29	Herabstufung	Needham	Strong Buy → Hold
2019-07-09	Herabstufung	Cowen	Outperform → Market Perform
2019-03-12	Bestätigt	Needham	Strong Buy
2019-01-03	Eingeleitet	Needham	Strong Buy
2018-11-30	Hochstufung	Goldman	Sell → Neutral
2018-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-07-11	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Eingeleitet	Goldman	Sell
2018-01-22	Bestätigt	Barclays	Equal Weight
2018-01-05	Eingeleitet	BTIG Research	Buy
2017-10-02	Fortgesetzt	Leerink Partners	Mkt Perform
2017-08-09	Bestätigt	Barclays	Equal Weight
2017-02-08	Hochstufung	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Eingeleitet	Deutsche Bank	Sell
2016-10-10	Herabstufung	Ladenburg Thalmann	Neutral → Sell

Alle ansehen

Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten

Mar 11, 2026

3 Reasons to Sell MYGN and 1 Stock to Buy Instead - Yahoo Finance

Mar 11, 2026

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance

Mar 11, 2026

Mar 10, 2026

Myriad Genetics at Leerink Conference: Strategic Moves in Cancer Care By Investing.com - Investing.com Canada

Mar 10, 2026

Trading Recap: Whats next for Myriad Genetics Inc stockBreakout Watch & Consistent Return Strategy Ideas - baoquankhu1.vn

Mar 06, 2026

Take Profit: What hedge funds are buying Myriad Genetics IncMarket Sentiment Review & Weekly High Momentum Picks - baoquankhu1.vn

Mar 06, 2026

Mar 05, 2026

Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN - MarketBeat

Mar 05, 2026

Mar 04, 2026

Myriad Genetics Stock Up on New Breast Cancer MRD Test Launch | 2026News and Statistics - IndexBox

Mar 04, 2026

MYGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026

Mar 03, 2026

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz

Mar 03, 2026

Mar 02, 2026

Myriad Commercially Launches Precise MRD with Select Community Oncologists - Bitget

Mar 02, 2026

Myriad Genetics (MYGN) CPO has shares withheld to cover taxes - Stock Titan

Mar 02, 2026

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Mar 02, 2026

Feb 28, 2026

Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research - MarketBeat

Feb 28, 2026

MYGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Feb 27, 2026

PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Yahoo Finance

Feb 27, 2026

Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares - MarketBeat

Feb 27, 2026

Insider Buying: Myriad Genetics (NASDAQ:MYGN) Director Acquires 6,100 Shares of Stock - MarketBeat

Feb 27, 2026

S. Louise Phanstiel Acquires 50,407 Shares of Myriad Genetics (NASDAQ:MYGN) Stock - MarketBeat

Feb 27, 2026

Myriad Genetics Insider Bought Shares Worth $494,722, According to a Recent SEC Filing - marketscreener.com

Feb 27, 2026

Director Phanstiel adds 104,507 Myriad Genetics (MYGN) shares - Stock Titan

Feb 27, 2026